Dietary-phytochemical mediated reversion of cancer-specific splicing inhibits Warburg effect in head and neck cancer.
Aged, 80 and over
Alternative Splicing
Antineoplastic Agents
/ pharmacology
Carcinoma, Squamous Cell
/ diet therapy
Carrier Proteins
/ genetics
Cell Line, Tumor
Curcumin
/ pharmacology
DNA (Cytosine-5-)-Methyltransferases
/ metabolism
DNA Methylation
DNA-Binding Proteins
/ metabolism
Epigenesis, Genetic
Female
Glycolysis
/ drug effects
Head and Neck Neoplasms
/ diet therapy
Humans
Male
Membrane Proteins
/ genetics
Middle Aged
Phytochemicals
/ therapeutic use
Protein Isoforms
/ genetics
Pyruvate Kinase
/ genetics
Thyroid Hormones
/ genetics
DNA Methyltransferase 3B
Thyroid Hormone-Binding Proteins
Alternative splicing
Curcumin
Head and neck cancer
PKM
Warburg effect
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
received:
11
04
2019
accepted:
14
10
2019
entrez:
3
11
2019
pubmed:
5
11
2019
medline:
21
3
2020
Statut:
epublish
Résumé
The deregulated alternative splicing of key glycolytic enzyme, Pyruvate Kinase muscle isoenzyme (PKM) is implicated in metabolic adaptation of cancer cells. The splicing switch from normal PKM1 to cancer-specific PKM2 isoform allows the cancer cells to meet their energy and biosynthetic demands, thereby facilitating the cancer cells growth. We have investigated the largely unexplored epigenetic mechanism of PKM splicing switch in head and neck cancer (HNC) cells. Considering the reversible nature of epigenetic marks, we have also examined the utility of dietary-phytochemical in reverting the splicing switch from PKM2 to PKM1 isoform and thereby inhibition of HNC tumorigenesis. We present HNC-patients samples, showing the splicing-switch from PKM1-isoform to PKM2-isoform analyzed via immunoblotting and qRT-PCR. We performed methylated-DNA-immunoprecipitation to examine the DNA methylation level and chromatin-immunoprecipitation to assess the BORIS (Brother of Regulator of Imprinted Sites) recruitment and polII enrichment. The effect of dietary-phytochemical on the activity of denovo-DNA-methyltransferase-3b (DNMT3B) was detected by DNA-methyltransferase-activity assay. We also analyzed the Warburg effect and growth inhibition using lactate, glucose uptake assay, invasion assay, cell proliferation, and apoptosis assay. The global change in transcriptome upon dietary-phytochemical treatment was assayed using Human Transcriptome Array 2.0 (HTA2.0). Here, we report the role of DNA-methylation mediated recruitment of the BORIS at exon-10 of PKM-gene regulating the alternative-splicing to generate the PKM2-splice-isoform in HNC. Notably, the reversal of Warburg effect was achieved by employing a dietary-phytochemical, which inhibits the DNMT3B, resulting in the reduced DNA-methylation at exon-10 and hence, PKM-splicing switch from cancer-specific PKM2 to normal PKM1. Global-transcriptome-analysis of dietary-phytochemical-treated cells revealed its effect on alternative splicing of various genes involved in HNC. This study identifies the epigenetic mechanism of PKM-splicing switch in HNC and reports the role of dietary-phytochemical in reverting the splicing switch from cancer-specific PKM2 to normal PKM1-isoform and hence the reduced Warburg effect and growth inhibition of HNC. We envisage that this approach can provide an effective way to modulate cancer-specific-splicing and thereby aid in the treatment of HNC.
Sections du résumé
BACKGROUND
BACKGROUND
The deregulated alternative splicing of key glycolytic enzyme, Pyruvate Kinase muscle isoenzyme (PKM) is implicated in metabolic adaptation of cancer cells. The splicing switch from normal PKM1 to cancer-specific PKM2 isoform allows the cancer cells to meet their energy and biosynthetic demands, thereby facilitating the cancer cells growth. We have investigated the largely unexplored epigenetic mechanism of PKM splicing switch in head and neck cancer (HNC) cells. Considering the reversible nature of epigenetic marks, we have also examined the utility of dietary-phytochemical in reverting the splicing switch from PKM2 to PKM1 isoform and thereby inhibition of HNC tumorigenesis.
METHODS
METHODS
We present HNC-patients samples, showing the splicing-switch from PKM1-isoform to PKM2-isoform analyzed via immunoblotting and qRT-PCR. We performed methylated-DNA-immunoprecipitation to examine the DNA methylation level and chromatin-immunoprecipitation to assess the BORIS (Brother of Regulator of Imprinted Sites) recruitment and polII enrichment. The effect of dietary-phytochemical on the activity of denovo-DNA-methyltransferase-3b (DNMT3B) was detected by DNA-methyltransferase-activity assay. We also analyzed the Warburg effect and growth inhibition using lactate, glucose uptake assay, invasion assay, cell proliferation, and apoptosis assay. The global change in transcriptome upon dietary-phytochemical treatment was assayed using Human Transcriptome Array 2.0 (HTA2.0).
RESULTS
RESULTS
Here, we report the role of DNA-methylation mediated recruitment of the BORIS at exon-10 of PKM-gene regulating the alternative-splicing to generate the PKM2-splice-isoform in HNC. Notably, the reversal of Warburg effect was achieved by employing a dietary-phytochemical, which inhibits the DNMT3B, resulting in the reduced DNA-methylation at exon-10 and hence, PKM-splicing switch from cancer-specific PKM2 to normal PKM1. Global-transcriptome-analysis of dietary-phytochemical-treated cells revealed its effect on alternative splicing of various genes involved in HNC.
CONCLUSION
CONCLUSIONS
This study identifies the epigenetic mechanism of PKM-splicing switch in HNC and reports the role of dietary-phytochemical in reverting the splicing switch from cancer-specific PKM2 to normal PKM1-isoform and hence the reduced Warburg effect and growth inhibition of HNC. We envisage that this approach can provide an effective way to modulate cancer-specific-splicing and thereby aid in the treatment of HNC.
Identifiants
pubmed: 31675998
doi: 10.1186/s12885-019-6257-1
pii: 10.1186/s12885-019-6257-1
pmc: PMC6823945
doi:
Substances chimiques
Antineoplastic Agents
0
CTCFL protein, human
0
Carrier Proteins
0
DNA-Binding Proteins
0
Membrane Proteins
0
Phytochemicals
0
Protein Isoforms
0
Thyroid Hormones
0
DNA (Cytosine-5-)-Methyltransferases
EC 2.1.1.37
Pyruvate Kinase
EC 2.7.1.40
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1031Subventions
Organisme : Board of Research in Nuclear Sciences
ID : 37(1)/14/30/2016-BRNS/37267
Organisme : The Wellcome Trust DBT India Alliance
ID : IA/I/16/2/502719
Références
Biochem Pharmacol. 2010 Apr 15;79(8):1118-24
pubmed: 20005212
Sci Rep. 2018 May 29;8(1):8323
pubmed: 29844464
Cell Res. 2013 Nov;23(11):1256-69
pubmed: 23938295
Curr Transl Geriatr Exp Gerontol Rep. 2012 Dec 1;1(4):229-236
pubmed: 23526405
Hum Mol Genet. 2001 Apr;10(7):687-92
pubmed: 11257100
Indian J Exp Biol. 1980 Jan;18(1):73-5
pubmed: 6772551
Oncotarget. 2014 Sep 30;5(18):8202-10
pubmed: 24077665
Nature. 2008 Mar 13;452(7184):230-3
pubmed: 18337823
Life Sci. 2006 Mar 27;78(18):2081-7
pubmed: 16413584
Cell Metab. 2008 Jan;7(1):11-20
pubmed: 18177721
Mol Cell Biol. 2011 Jan;31(1):138-50
pubmed: 21041478
Eur J Cancer. 2012 Apr;48(6):929-35
pubmed: 22019212
Sci Rep. 2016 Nov 24;6:37727
pubmed: 27883057
Biochim Biophys Acta. 2014 Dec;1840(12):3494-3502
pubmed: 25240776
Br J Cancer. 2011 May 24;104(11):1755-61
pubmed: 21505451
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Nature. 2008 Nov 27;456(7221):470-6
pubmed: 18978772
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
J Cell Physiol. 2018 Jun;233(6):4634-4642
pubmed: 28926094
Oncogene. 2002 Aug 12;21(35):5496-503
pubmed: 12154410
Biochim Biophys Acta. 2012 Jul;1819(7):673-83
pubmed: 22326677
Nature. 2010 Jan 21;463(7279):364-8
pubmed: 20010808
In Vivo. 2010 Jul-Aug;24(4):401-8
pubmed: 20668306
J Mol Cell Biol. 2012 Apr;4(2):79-87
pubmed: 22044881
Phytother Res. 2013 Mar;27(3):422-30
pubmed: 22628241
Postdoc J. 2017 Jan;5(1):14-28
pubmed: 28191478
Clin Cancer Res. 2012 Oct 15;18(20):5554-61
pubmed: 23071357
Oncogene. 2002 Aug 12;21(35):5483-95
pubmed: 12154409
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
pubmed: 15761078
PLoS One. 2013;8(2):e55934
pubmed: 23457487
Oncotarget. 2015 May 20;6(14):11806-19
pubmed: 25909219
Cell Rep. 2015 Feb 24;10(7):1122-34
pubmed: 25704815
Oncotarget. 2015 Aug 14;6(23):19469-82
pubmed: 26254223
Biochim Biophys Acta. 1996 Nov 15;1317(2):95-100
pubmed: 8950193
Nature. 2011 Nov 3;479(7371):74-9
pubmed: 21964334
Mol Oncol. 2012 Dec;6(6):620-36
pubmed: 23141800
Biomacromolecules. 2016 Jul 11;17(7):2375-83
pubmed: 27192144
Cancer Res. 2014 Feb 1;74(3):954-63
pubmed: 24351292
Annu Rev Biochem. 2015;84:165-98
pubmed: 26034889
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Clin Cancer Res. 2015 Jan 15;21(2):233-9
pubmed: 25104085
EMBO Rep. 2016 Dec;17(12):1721-1730
pubmed: 27856534
Adv Exp Med Biol. 2011;720:91-104
pubmed: 21901621
Int J Mol Sci. 2018 Sep 25;19(10):null
pubmed: 30257458
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11440-11445
pubmed: 29073069
EMBO Rep. 2016 Jul;17(7):1061-80
pubmed: 27255086
PLoS One. 2013;8(2):e57709
pubmed: 23460897
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683